SVANasdaqPharmaceutical PreparationsFiscal year ends December 31

SINOVAC BIOTECH LTD

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Jun 5, 2026

$6.47+0.00 (0.00%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: 850.08%

SINOVAC BIOTECH LTD income statement

AnnualQuarterlyTTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	386	361	470	1,473	19,365	511	246	230	174	72	67	63	72	49	57	33	84
Cost of Revenue	124	141	147	658	989	67	32	25	20	22	18	15	21	19	21	17	20
Gross Profit	262	221	323	815	18,376	443	214	205	154	50	49	47	51	30	36	17	64
Research & Development	216	271	350	479	153	49	24	22	20	13	9.49	11	8.13	17	9.01	8.51	4.41
Selling, General & Admin	333	421	598	836	602	177	121	137	87	42	37	34	34	33	24	19	18
Advertising Expenses	1.17	1.02	1.88	7.67	9.02	0.86	1.40	3.90	4.01	3.34	2.78	1.97	0.47	0.03	0.01	0.04	–
Operating Expenses	752	726	1,037	1,324	758	228	145	160	109	50	45	46	41	51	32	30	22
Operating Income	-490	-506	-714	-509	17,618	216	69	45	45	0.50	3.70	1.89	9.95	-21	3.37	-13	42
Interest & Investment Income	33	29	87	157	103	1.93	2.00	2.02	1.18	0.73	1.16	2.68	2.17	2.37	1.40	1.13	0.14
Income from Equity Investments	-4.04	-2.70	-11	7.76	2.63	–	–	–	–	–	–	–	–	–	–	–	–
Other Non-Operating Income	209	528	559	297	-153	0.50	0.91	0.32	0.01	0.10	-0.17	1.19	–	–	–	–	–
Asset Impairment Charges	0	0	0	0	–	–	–	–	–	–	0	0	0.06	2.18	0.42	–	–
Gain (Loss) on Sale of Assets	–	-30	-109	-5.88	-0.98	-0.16	-0.29	-0.08	-0.04	-0.48	0.03	0.07	0.03	-0.01	-0.04	-1.24	-0.17
Pretax Income	-262	43	-84	-48	17,568	217	71	47	45	-0.39	2.76	2.35	9.41	-20	4.67	-13	42
Income Tax Expense	-63	2.18	36	11	3,448	31	5.61	10	8.34	2.66	2.99	2.07	-2.23	-0.88	5.07	-0.70	11
Income from Continuing Operations	–	–	–	–	–	–	–	22	26	-2.93	-0.69	0.01	8.71	–	–	–	–
Income from Discontinued Operations	–	–	–	–	–	–	–	0	0	0	-0.73	-1.52	-1.27	–	–	–	–
Net Income incl. Noncontrolling Interests	-199	41	-121	-60	14,120	185	65	36	37	-0.72	-0.96	-1.25	10	-19	-0.40	-13	30
Minority Interest in Earnings	-139	-50	-107	-74	5,998	75	20	14	11	-0.12	0.46	0.27	2.93	-3.90	0.45	-4.09	-10
Net Income	–	–	-13	14	8,122	110	45	22	26	-0.60	-1.42	-1.52	7.44	–	-0.84	-8.51	20
Net Income to Common	-60	91	-13	14	8,122	104	40	22	26	-0.60	-1.42	-1.52	7.44	-15	-0.84	-8.51	20
EPS (Basic)(per share)	-0.83	1.27	-0.19	0.20	113.54	1.06	0.42	0.34	0.45	-0.01	-0.03	-0.03	0.13	-0.27	-0.02	-0.16	0.47
EPS (Diluted)(per share)	-0.83	1.27	-0.19	0.20	113.44	0.97	0.41	0.34	0.45	-0.01	-0.03	-0.03	0.13	-0.27	-0.02	-0.16	0.46
Shares Outstanding (Basic, Weighted)(shares)	72	72	72	72	72	99	95	65	57	57	56	56	55	55	55	53	43
Shares Outstanding (Diluted, Weighted)(shares)	72	72	72	72	72	114	110	65	57	57	56	56	56	55	55	53	43
Dividend per Share(per share)	55.00	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
EBITDA	–	–	–	–	–	–	–	–	–	–	–	–	–	-17	8.20	-9.12	44
Net Investment Income	–	–	248	0	0	–	–	–	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Dec 31, 2025

Profitability, FY2025

Gross margin: 67.9%
Operating margin: -127.0%
Net margin: –
Return on equity, FY2025: –

Financial strength

Current ratio: 4.59
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 31.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: 850.08%